{"name": "Movetis",
 "permalink": "movetis",
 "crunchbase_url": "http://www.crunchbase.com/company/movetis",
 "homepage_url": "http://www.movetis.com/",
 "blog_url": "",
 "blog_feed_url": "http://www.movetis.com/movetis-news-feeds",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2006,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "32 1 440 43 90",
 "description": "Pharmaceutical Developer ",
 "created_at": "Fri Dec 04 01:59:48 UTC 2009",
 "updated_at": "Tue Apr 20 04:02:49 UTC 2010",
 "overview": "\u003Cp\u003EMovetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company\u00e2\u20ac\u2122s lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient\u00e2\u20ac\u2122s refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       57],
      "assets/images/resized/0006/8511/68511v1-max-150x150.png"],
     [[213,
       81],
      "assets/images/resized/0006/8511/68511v1-max-250x250.png"],
     [[213,
       81],
      "assets/images/resized/0006/8511/68511v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO and Co-founder",
    "person":
     {"first_name": "Dirk",
      "last_name": "Reyn",
      "permalink": "dirk-reyn",
      "image": null}},
   {"is_past": false,
    "title": " Co-Founder and Chairman of the Board ",
    "person":
     {"first_name": "Staf",
      "last_name": "Van Reet",
      "permalink": "staf-van-reet",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$177M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=32\u0026aid=DJFVW00020091203e5c4000rt\u0026r=Rss\u0026s=DJFVW",
    "source_description": "Belgian Pharma Co. Movetis Raises $127.5M In IPO  ",
    "raised_amount": 127500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 12,
    "funded_day": 3,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Credit Suisse",
         "permalink": "credit-suisse",
         "image":
          {"available_sizes":
            [[[150,
               27],
              "assets/images/resized/0002/9146/29146v1-max-150x150.jpg"],
             [[175,
               32],
              "assets/images/resized/0002/9146/29146v1-max-250x250.jpg"],
             [[175,
               32],
              "assets/images/resized/0002/9146/29146v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "a",
    "source_url": "http://www.bip.lu/opsmain/download/movetis.pdf",
    "source_description": "MOVETIS NV Closes 49 Million EUR Series A Financing Round",
    "raised_amount": 49000000.0,
    "raised_currency_code": "EUR",
    "funded_year": 2007,
    "funded_month": 1,
    "funded_day": 8,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Sofinnova Partners",
         "permalink": "sofinnova-partners",
         "image":
          {"available_sizes":
            [[[150,
               20],
              "assets/images/resized/0004/4451/44451v1-max-150x150.jpg"],
             [[250,
               33],
              "assets/images/resized/0004/4451/44451v1-max-250x250.jpg"],
             [[321,
               43],
              "assets/images/resized/0004/4451/44451v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Life Sciences Partners",
         "permalink": "life-sciences-partners",
         "image":
          {"available_sizes":
            [[[146,
               66],
              "assets/images/resized/0004/7976/47976v1-max-150x150.jpg"],
             [[146,
               66],
              "assets/images/resized/0004/7976/47976v1-max-250x250.jpg"],
             [[146,
               66],
              "assets/images/resized/0004/7976/47976v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Sofinnova Ventures",
         "permalink": "sofinnova-ventures",
         "image":
          {"available_sizes":
            [[[150,
               26],
              "assets/images/resized/0003/0428/30428v1-max-150x150.jpg"],
             [[194,
               34],
              "assets/images/resized/0003/0428/30428v1-max-250x250.jpg"],
             [[194,
               34],
              "assets/images/resized/0003/0428/30428v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "KBC",
         "permalink": "kbc",
         "image":
          {"available_sizes":
            [[[109,
               104],
              "assets/images/resized/0005/9128/59128v1-max-150x150.jpg"],
             [[109,
               104],
              "assets/images/resized/0005/9128/59128v1-max-250x250.jpg"],
             [[109,
               104],
              "assets/images/resized/0005/9128/59128v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Gimv",
         "permalink": "gimv",
         "image":
          {"available_sizes":
            [[[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-150x150.jpg"],
             [[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-250x250.jpg"],
             [[65,
               90],
              "assets/images/resized/0004/8587/48587v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Quest for Growth",
         "permalink": "quest-for-growth",
         "image":
          {"available_sizes":
            [[[150,
               139],
              "assets/images/resized/0004/3753/43753v1-max-150x150.png"],
             [[200,
               186],
              "assets/images/resized/0004/3753/43753v1-max-250x250.png"],
             [[200,
               186],
              "assets/images/resized/0004/3753/43753v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "BIP Investment Partners",
         "permalink": "bip-investment-partners",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0004/6311/46311v1-max-150x150.jpg"],
             [[250,
               57],
              "assets/images/resized/0004/6311/46311v1-max-250x250.jpg"],
             [[263,
               61],
              "assets/images/resized/0004/6311/46311v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition":
  {"price_amount": 565000000.0,
   "price_currency_code": "USD",
   "term_code": null,
   "source_url": "http://www.fiercebiotech.com/story/shire-forges-565m-buyout-deal-movetis/2010-08-03?utm_medium=rss\u0026utm_source=rss",
   "source_description": "Shire forges $565M buyout deal for Movetis",
   "acquired_year": 2010,
   "acquired_month": 8,
   "acquired_day": 3,
   "acquiring_company":
    {"name": "Shire",
     "permalink": "shire",
     "image":
      {"available_sizes":
        [[[150,
           44],
          "assets/images/resized/0009/6378/96378v1-max-150x150.png"],
         [[150,
           44],
          "assets/images/resized/0009/6378/96378v1-max-250x250.png"],
         [[150,
           44],
          "assets/images/resized/0009/6378/96378v1-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Veedijk 58 1004",
    "address2": "",
    "zip_code": "2300",
    "city": "Turnhout",
    "state_code": null,
    "country_code": "BEL",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        82],
       "assets/images/resized/0006/8510/68510v1-max-150x150.jpg"],
      [[250,
        137],
       "assets/images/resized/0006/8510/68510v1-max-250x250.jpg"],
      [[450,
        246],
       "assets/images/resized/0006/8510/68510v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}